How does neratinib (neratinib) work? Is it effective in treating breast cancer?

Neratinib (Neratinib) is a targeted therapy drug, a tyrosine kinase inhibitor (TKI), mainly used to treat breast cancer. It blocks the proliferation signals of cancer cells by inhibiting HER2 (human epidermal growth factor receptor 2)-related tyrosine kinases, thereby limiting the growth and spread of cancer cells. The role of neratinib in the treatment of breast cancer is mainly reflected in its efficacy in patients with HER2 positive breast cancer, especially those who have received standard treatments but still have cancer cell recurrence.

Research shows that neratinib has good efficacy in both early and advanced HER2 positive breast cancer. Especially in postoperative adjuvant therapy, neratinib can significantly reduce the risk of breast cancer recurrence and prolong disease-free survival. Neratinib has also shown strong anti-tumor effects in the treatment of advanced or metastatic HER2-positive breast cancer. In clinical trials, neratinib was used in combination with traditional chemotherapy drugs to effectively reduce tumor volume, and some patients even experienced complete remission.

However, despite the strong efficacy of neratinib, some patients may experience some adverse reactions during use, such as diarrhea, fatigue, decreased appetite, etc. These side effects, although common, can often be alleviated with medication modification or symptomatic treatment. In order to obtain the best therapeutic effect, patients need to strictly follow the dosage requirements under the guidance of a doctor, conduct regular examinations, and adjust the treatment plan in a timely manner.

Overall, the therapeutic effect of neratinib is particularly significant for HER2 patients with positive breast cancer. It not only provides new treatment options for patients who are refractory to traditional treatments, but also brings new hope for personalized treatment of breast cancer. As more clinical data accumulates, the application prospects of neratinib may become broader and help more patients improve survival rates and quality of life.

Reference:https://en.wikipedia.org/wiki/Neratinib